In a setback for PTC Therapeutics, the Washington State Drug Utilization Review Board has decided to recommend another medicine for treating Duchenne muscular dystrophy rather than a similar but highly controversial drug that the company recently agreed to purchase.
The board on Wednesday endorsed a policy by the Washington State Health Care Authority, which administers the state Medicaid program, that prednisone is the “lower cost, equally effective alternative” to Emflaza, the drug that PTC agreed to buy for at least $140 million last month from Marathon Pharmaceuticals.
About the Author Reprints
